alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1–25 of 30 studies with an author at Sichuan University (CN) (page 1 of 2) · 27,380 in the whole library · How the 0–100 score works

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Other institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

6-month consequences of COVID-19 in patients discharged from hospital: a cohort study

✓ Peer-reviewed alzhub usefulness score 74 out of 100. Lancet (London, England) 2021-01-08

After multivariable adjustment, patients showed an odds ratio (OR) 1·61 (95% CI 0·80-3·25) for scale 4 versus scale 3 and 4·60 (1·85-11·48) for scale 5-6 versus scale 3 for diffusion impairment; OR 0·88 (0·66-1·17) for scale 4 versus scale 3 and OR 1·77 (1·05-2·97) for scale 5-6 versus scale 3 for anxiety or depression, and OR 0·74 (0·58-0·96) for scale 4 versus scale 3 and 2·69 (1·46-4·96) for scale 5-6 versus scale 3 for fatigue or muscle weakness. 2 key findings →

Design: cohort study Participants: 94 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Peripheral GFAP and NfL as early biomarkers for dementia: longitudinal insights from the UK Biobank

✓ Peer-reviewed alzhub usefulness score 69 out of 100. BMC medicine 2024-05-13

Peripheral glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) are sensitive markers of neuroinflammation and neuronal damage. 4 key findings →

Design: cohort study Participants: 48,542 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Effective dosage and mode of exercise for enhancing cognitive function in Alzheimer's disease and dementia: a systematic review and Bayesian Model-Based Network Meta-analysis of RCTs

✓ Peer-reviewed alzhub usefulness score 64 out of 100. BMC Geriatrics 2024-06-01

Nonlinear dose-response relationship between exercise and cognitive improvement in Alzheimer's disease, with the optimal AE dose identified at 660 METs-min/week for enhancing cognitive function in AD. 3 key findings →

Design: meta-analysis Participants: 2,242 Evidence: early

Full summary, score breakdown and related studies → Original source Free full text

Validation of neuropsychological tests for the China Health and Retirement Longitudinal Study Harmonized Cognitive Assessment Protocol

✓ Peer-reviewed alzhub usefulness score 61 out of 100. International psychogeriatrics 2019-07-16

We recruited 825 individuals from the CHARLS sample and 766 subjects from hospitals in six provinces and cities in China. 4 key findings →

Design: longitudinal study Participants: 825 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Social support interventions for caregivers of older adults with dementia: a scoping review

✓ Peer-reviewed alzhub usefulness score 61 out of 100. BMJ Open 2025-06-01

A total of 31 studies were selected for this review, revealing six distinct categories of social support interventions for caregivers of older adults with dementia. 5 key findings →

Design: meta-analysis Participants: 31 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Potential association between frailty and pTau in community-dwelling older adults

✓ Peer-reviewed alzhub usefulness score 59 out of 100. BMC geriatrics 2022-09-26

Among the 12 biomarkers, only pTau was higher in frail individuals than in their not-frail peers (471.3 ± 58.1 pg/mL vs. 451.9 ± 61.1 pg/mL, p = 0.022). 4 key findings →

Design: longitudinal study Participants: 313 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Prevalence of mental disorders in China: a cross-sectional epidemiological study

✓ Peer-reviewed alzhub usefulness score 58 out of 100. The lancet. Psychiatry 2019-02-18

Anxiety disorders were the most common class of disorders both in the 12 months before the interview (weighted prevalence 5·0%, 4·2-5·8) and in lifetime (7·6%, 6·3-8·8). 5 key findings →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Voxelwise meta-analysis of gray matter anomalies in Alzheimer's disease and mild cognitive impairment using anatomic likelihood estimation

✓ Peer-reviewed alzhub usefulness score 58 out of 100. Journal of the neurological sciences 2012-03-03

Our meta-analysis identified similar distributions of neuroanatomical changes in AD and MCI, which are consistent with the hierarchical model of neuropathological alterations of neurofibrillary tangles in AD and MCI. 2 key findings →

Design: systematic review Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Apolipoprotein E4 impairs the response of neurodegenerative retinal microglia and prevents neuronal loss in glaucoma

✓ Peer-reviewed alzhub usefulness score 54 out of 100. Immunity 2022-08-16

The apolipoprotein E4 (APOE4) allele is associated with an increased risk of Alzheimer disease and a decreased risk of glaucoma, but the underlying mechanisms remain poorly understood. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Poor glymphatic function is associated with mild cognitive impairment and its progression to Alzheimer's disease: A DTI-ALPS study

✓ Peer-reviewed alzhub usefulness score 53 out of 100. The Journal of Prevention of Alzheimer s Disease 2025-04-11

• Low ALPS index was significantly associated with high risk of MCI, and the risk of MCI decreased linearly with a higher ALPS index • High ALPS index was dose-dependently associated with a decreased progression from MCI to AD • High ALPS index may delay the MCI onset approximately 3.8 years among CN participants and delay MCI progression to AD by approximately 3.5 years in MCI group • Aβ in choroid plexus, tau in part of the cortex and executive function were partially mediate ALPS-AD association We aimed to explore the association between ALPS index and both risks of MCI from cognitively normal (CN) and incident AD progressed from MCI, as well as potential mediating factors. 1 key finding →

Participants: 519 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Blood biomarkers of vascular dysfunction in small vessel disease progression: Insights from a longitudinal neuroimaging study

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Alzheimer s & Dementia 2025-04-01

In linear mixed models, vascular endothelial growth factor was significantly associated with incident DWI-positive lesions over 1 year. 5 key findings →

Design: cross-sectional Participants: 181 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Head-to-head comparison of plasma biomarker assays across platforms for amyloid pathology in a multicenter cohort

✓ Peer-reviewed alzhub usefulness score 52 out of 100. 中国科学通报：英文版 2026-08-06

With the advancement of anti-amyloid treatments for Alzheimer disease, accurate assays for amyloid-β (Aβ) pathology are essential. 1 key finding →

Design: cross-sectional Participants: 431 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Global burden of young-onset dementia, from 1990 to 2021: an age-period-cohort analysis from the global burden of disease study 2021

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Translational Psychiatry 2025-02-17

This study aims to assess the burden of young-onset dementia worldwide, regionally, and nationally during 1990-2021. 5 key findings →

Participants: 100,000 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Diabetes and its complications: molecular mechanisms, prevention and treatment

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Signal Transduction and Targeted Therapy 2026-01-19

Diabetic complications represent a formidable clinical challenge characterized by hyperglycemia-induced multiorgan dysfunction and dysregulated intercellular signaling networks. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Pain, agitation, and delirium practices in Chinese intensive care units: A national multicenter survey study

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Chinese Medical Journal 2025-10-24

To the Editor: The standardized management of pain–agitation–delirium (PAD) represents a fundamental component of clinical practice in intensive care units (ICUs).[1] Evidence-based analgesia and sedation strategies not only alleviate patients’ physiological discomfort and psychological distress, but also significantly reduce mechanical ventilation duration, improve long-term prognosis, and optimize healthcare resource allocation.[1,2] Equally crucial is delirium management, as evidenced by studies demonstrating that delirium duration independently predicts mortality risk, hospital stay length, healthcare expenditures, and acquired dementia incidence.[3] Although existing studies have explored PAD management practices, most rely on clinicians’ subjective recall that may distort objective clinical realities and fail to reflect distinctive characteristics.[4] Therefore, this nationwide multicenter cross-sectional study, initiated by the Critical Care Analgesia and Sedation Quality Control Subspecialty Group under the China National Center for Medical Quality Control in Critical Care Medicine, aims to investigate the current status of PAD management in China. 5 key findings →

Design: cross-sectional Participants: 2,627 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Tongxinluo capsule in the treatment of cerebral small vessel disease: protocol of a randomised, double-blind, placebo-controlled, multicentre clinical study (TOPS-CSVD)

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Stroke and Vascular Neurology 2025-09-10

The primary outcome of this clinical trial is the change in the Vascular Dementia Assessment Scale-cognitive subscale from baseline to 12 months. 3 key findings →

Participants: 1,052 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

The temporal trend and distribution characteristics in mortality of Alzheimer's disease and other forms of dementia in China: Based on the National Mortality Surveillance System (NMS) from 2009 to 2015

✓ Peer-reviewed alzhub usefulness score 44 out of 100. PLoS ONE 2019-01-31

In China, the crude mortality from AD and other forms of dementia increased from 2009 to 2015, but the age-standardized mortality decreased. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Retinal biomarkers for the risk of Alzheimer’s disease and frontotemporal dementia

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Frontiers in Aging Neuroscience 2025-01-10

Our findings provide preliminary empirical support for a relationship between prodromal changes in retinal layers and a higher risk of AD or FTD, suggesting that macular OCT may serve as a non-invasive, sensitive biomarker of high-risk years before the onset of dementia. 3 key findings →

Participants: 148 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Retinal microvascular dysfunction in mild cognitive impairment: Associations with cerebral small vessel disease, plasma biomarkers, and cognitive decline

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Alzheimer s & Dementia 2026-02-01

MCI exhibited greater retinal tortuosity (p < 0.05) and sparser vasculature (p < 0.001), correlating with higher PSMD, WMH volumes, and adverse plasma biomarkers (all p < 0.05). 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Exploration of working memory retrieval stage for mild cognitive impairment: time-varying causality analysis of electroencephalogram based on dynamic brain networks

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Journal of NeuroEngineering and Rehabilitation 2025-03-13

Our results showed that: (a) Behavioral data analysis: there were significant differences in accuracy and accuracy / reaction time between MCI and NC in tasks with memory load capacity of low load-four and high load-six, especially in tasks with memory load capacity of four. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed